關於bevacizumab(Avastin®)安全性的最新資訊 Latest safety update on bevacizumab(Avastin®)

    Bevacizumab(Avastin®)是用於對抗血管內皮生長因子(VEGF)的重組人單克隆抗體(recombinant humanized monoclonal antibody), 加拿大衛生部(Health Canada)與羅氏公司(Roche)近日發佈了關於其安全性的最新資訊。最近臨床試驗的發現指出, 高達5%接受bevacizumab的病人出現了嚴重的過敏反應和輸注反應, 症狀包括窒息﹑面潮紅/皮疹﹑低血壓或高血壓﹑缺氧﹑胸痛﹑寒戰以及噁心/嘔吐。因此, 加拿大衛生部提醒醫生及其他衛生專業人士:

1. 於輸注bevacizumab期間及用藥後, 嚴密監測病人有否出現上述症狀。

2. 如病人發生輸注反應, 應停止輸注bevacizumab以及採取適當的治療措施。

                                                                                                                                                                                                                                                                              

    Both Health Canada and Roche, Canada jointly announced the latest safety update on bevacizumab (Avastin®), a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF).  Recent findings from the clinical trials identified serious hypersensitivity and infusion reactions up to 5% in bevacizumab -treated patient including dyspnea, flushing/redness/rash, hypotension or hypertension, oxygen desaturation, chest pain, rigors, and nausea/vomiting. Thus, Health Canada would remind prescribers and healthcare professionals about the following:

1. Patients should be closely monitored for signs and symptoms as described above during and following the administration of bevacizumab infusion .

2. If a reaction occurs, bevacizumab should be interrupted and appropriate medical therapies should be initiated.

 

 

參考資料/References and websites:

https://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/avastin_5_hpc-cps-eng.php

https://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2010/avastin_5_pc-cp-eng.php


Free Counter
Free Counter